Eisai Co. Ltd.

In News

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan - Eisai

Eisai - Jun 02, 2025

EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY - prnewswire.com

prnewswire.com - Mar 26, 2026

Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer - BioPharma APAC

BioPharma APAC - Mar 29, 2026

Don't Race Out To Buy Eisai Co., Ltd. (TSE:4523) Just Because It's Going Ex-Dividend - simplywall.st

simplywall.st - Mar 26, 2026

We’re teaming up with Eisai to help fight cancer - merck.com

merck.com - Mar 12, 2026

Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - reuters.com

reuters.com - Feb 05, 2026

Eisai Co., Ltd. 2026 Q3 - Results - Earnings Call Presentation (OTCMKTS:ESAIY) 2026-02-09 - Seeking Alpha

Seeking Alpha - Feb 09, 2026

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency - en.acnnewswire.com

en.acnnewswire.com - Mar 27, 2026

CD73-targeting immunoconjugates disclosed in Eisai patent - bioworld.com

bioworld.com - Mar 16, 2026

Eisai Co Ltd And Biogen Inc Announce Real-World Long-Term Treatment Persistence With Leqembi - marketscreener.com

marketscreener.com - Mar 20, 2026

Eisai and Biogen Report High Treatment Persistence for Lecanemab in Real-World Alzheimer's Patients - Quiver Quantitative

Quiver Quantitative - Mar 20, 2026

Eisai begins enrollment for narcolepsy drug E2086 phase 2 study - investing.com

investing.com - Mar 26, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment